Submit a Proposal

Step One

Download a Letter of Intent for the award you are applying to.

Step Two

Complete the Letter of Intent providing the title of the proposed research or educational project, a 500-word description, and a budget estimate.

Hints on writing a successful grant

Examples of successful Letters of Intent

Step Three

E-mail completed Letters of Intent should be submitted to the Program Administrator at:

programadministrator@bayer-hemophilia-awards.com and
bayer-hemophilia-awards@porterhouse.biz (please send to both addresses)

Letters of Intent will be reviewed by all members of the Grants Review and Awards Committee. Applicants submitting acceptable Letters of Intent will be asked by the Committee to submit a full proposal.

Applicants invited to submit a full proposal will receive the full application form by e-mail.

Next Steps

Full Proposal

If your Letter of Intent is accepted by the Committee, you will receive, by e-mail, the full proposal form. The latter will be a Word document. You should complete the full proposal form before emailing the document to the Program Administrator. There may be a requirement for you to include other documents with your form, e.g. a CV. These should be cut and pasted into your form so that you submit a single Word document.

If a given section does not apply to your proposal, please write 'not applicable' in the appropriate space, so we can be sure it was not left blank in error.

Feedback from the Grants Review and Awards Committee is available to all individuals who complete a full proposal whether or not an award is made.

We appreciate your interest in The Bayer Hemophilia Awards Program and in improving the lives of people with bleeding disorders. The Bayer Hemophilia Awards Program demonstrates Bayer's commitment to the bleeding disorders community and to advancing the state of the art of hemophilia care.

The Program is an important and reliable source of educational and research funding for health professionals in the bleeding disorders community.

We look forward to a continuing partnership with hemophilia caregivers and researchers around the world to support the next steps for the next generation of care and treatment options for people with hemophilia.